Covid vaccine maker BioNTech has reported sharp falls in revenue and profits compared with last year amid waning global demand for the jabs.
The German biotech company on Monday reported revenues of €3.5bn for the three months to September 30, down from around €6.1bn for the same period last year. Net profit fell from €3.2bn in the third quarter of 2021 to about €1.8bn.
The group also updated its forecast for vaccine revenues for 2022, from previous guidance of between €13bn and €17bn to a narrower range of €16bn-€17bn. Last year it made €19bn in vaccine revenues.
您已閱讀26%（568字），剩餘74%（1606字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。